Cargando…
Case report of PLXNA4 variant associated with hyper-response to phentermine/topiramate pharmacotherapy: Potential genetic basis for superior weight loss response?
BACKGROUND: Once thought to be primarily a result of lifestyle, it is now known that obesity has significant genetic components. Dozens of genes have been linked to obesity, and office-based genetic testing for obesity-associated genes is now readily available. As both pharmacotherapy and genetic te...
Autores principales: | Paszkowiak, Maria, Dorand, Madisen Fae, Richards, Jesse |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662083/ https://www.ncbi.nlm.nih.gov/pubmed/37990741 http://dx.doi.org/10.1016/j.obpill.2023.100059 |
Ejemplares similares
-
Formulary Management of 2 New Agents: Lorcaserin and Phentermine/Topiramate for Weight Loss
por: Kelly, Elizabeth M., et al.
Publicado: (2013) -
Phentermine and topiramate for the management of obesity: a review
por: Cosentino, Gina, et al.
Publicado: (2011) -
Phentermine-topiramate: First combination drug for obesity
por: Singh, Jagjit, et al.
Publicado: (2015) -
Cardiovascular Safety During and After Use of Phentermine and Topiramate
por: Ritchey, Mary E, et al.
Publicado: (2018) -
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
por: Shin, Jin Hee, et al.
Publicado: (2013)